| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
|
Rubinstein, Paul G
|
|
|
10 |
8 |
p. e624-e632
|
article
|
| 2 |
Correction to Lancet Haematol 2023; 10: e492–94
|
|
|
|
10 |
8 |
p. e574
|
article
|
| 3 |
Correction to Lancet Haematol 2023; 10: e585–99
|
|
|
|
10 |
8 |
p. e574
|
article
|
| 4 |
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
|
Piel, Frédéric B
|
|
|
10 |
8 |
p. e633-e686
|
article
|
| 5 |
Ending the burden of sickle cell disease in Africa
|
Moeti, Matshidiso R
|
|
|
10 |
8 |
p. e567-e569
|
article
|
| 6 |
European Hematology Association 2023 Hybrid Congress
|
del Pozo Martín, Yaiza
|
|
|
10 |
8 |
p. e575-e576
|
article
|
| 7 |
Global advocacy from Zambia for the hopes and dreams of people with sickle cell disease
|
Kasongo, Lwimba
|
|
|
10 |
8 |
p. e583-e584
|
article
|
| 8 |
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
|
|
|
|
10 |
8 |
p. e585-e599
|
article
|
| 9 |
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem
|
Leebeek, Frank W G
|
|
|
10 |
8 |
p. e561-e562
|
article
|
| 10 |
International Society on Thrombosis and Haemostasis Congress 2023
|
Cookson, Emma
|
|
|
10 |
8 |
p. e577-e578
|
article
|
| 11 |
Mental health and psychological resilience in sickle cell disease
|
Treadwell, Marsha J
|
|
|
10 |
8 |
p. e569-e571
|
article
|
| 12 |
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia
|
Yilmaz, Musa
|
|
|
10 |
8 |
p. e559-e561
|
article
|
| 13 |
Optimising treatment of HIV-associated Hodgkin lymphoma
|
Hoffmann, Christian
|
|
|
10 |
8 |
p. e563-e564
|
article
|
| 14 |
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong
|
Odame, Isaac
|
|
|
10 |
8 |
p. e579-e580
|
article
|
| 15 |
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial
|
Ragni, Margaret V
|
|
|
10 |
8 |
p. e612-e623
|
article
|
| 16 |
Sickle cell disease in the Caribbean: progress in newborn screening, clinical care, and research through collaboration
|
Knight-Madden, Jennifer
|
|
|
10 |
8 |
p. e581-e582
|
article
|
| 17 |
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
|
Mañú Pereira, María del Mar
|
|
|
10 |
8 |
p. e687-e694
|
article
|
| 18 |
Sickle cell disease: time to act on the most neglected global health problem
|
Osei, Miriam A
|
|
|
10 |
8 |
p. e558-e559
|
article
|
| 19 |
Sickle cell disease—unity and patient-centred education
|
The Lancet Haematology,
|
|
|
10 |
8 |
p. e557
|
article
|
| 20 |
Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease
|
Porter, Jerlym S
|
|
|
10 |
8 |
p. e571-e573
|
article
|
| 21 |
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
|
Xuan, Li
|
|
|
10 |
8 |
p. e600-e611
|
article
|
| 22 |
The Lancet Haematology Commission on sickle cell disease: key recommendations
|
|
|
|
10 |
8 |
p. e564-e567
|
article
|
Journal description